Four things to avoid amid Hepatitis A outbreak caused by supermarket food item
An investigation has been launched after a 'contaminated' supermarket item has led to a worrying outbreak of Hepatitis A - Brits have been warned to avoid four specific things
A mysterious supermarket item has been linked to a worrying hepatitis outbreak that has left 58 Brits in hospital - and people have been warned to avoid four specific things.
An investigation was launched after a "contaminated" item and outbreak is believed to have left as many as 95 people ill. The UK Health Security Agency confirmed two different clusters of the virus have been identified. Brits have been given a list of things they should avoid if they want to steer away from catching hepatitis A. Investigators are working to uncover the origins of the outbreak - which has reported 54 cases since 2024.
This report said: "A particular food item purchased from a particular supermarket has emerged as a possible vehicle of transmission due to its frequent reported consumption." The supermarket item has not been named, despite officials having concerns it is a "possible vehicle of transmission".
Hepatitis A is a liver infection which spreads in the poo of an infected person, according to the NHS. The infection is uncommon in the UK but Brits have been warned about four ways they could catch Hepatitis A.
Hepatitis A can be caught by:
drinking unclean water
eating food that's been washed or grown in unclean water
eating food that's been handled by an infected person
close physical contact with an infected person, including having sex and sharing needles to take drugs
The infection can lead to weakness, fatigue, a loss of appetite, nausea, vomiting and diarrhoea, fever jaundice and abdominal pain. If left untreated, the infection could lead to liver problems in a small number of people. These problems could lead to liver failure and, in some circumstances, could be fatal.
Hepatitis A usually clears up on its own between three to six months and doctors could offer medicines to infected people to help with certain symptoms. The NHS recommends people who have contracted the infection should not drink alcohol, prepare food or drink for other people, and should not share needles with others.
People with symptoms have also been advised to limit contact with people for a week after their symptoms start, drink plenty of fluids and wash their hands thoroughly after going to the toilet, according to the NHS.
The first cluster of the outbreak - in which cases were identified between January 2021 and March 2025 - of the hepatitis outbreak saw 19 people be hospitalised with the infection. Most people in the first group were aged between 50 and 69.
The second wave of infections started in January 2023 with cases still being reported in March this year. No deaths have been linked to the report as of yet.
Public Health Scotland is taking the lead in the investigation alongside officials with the UKHSA. Hepatitis is more common in parts of the world like Africa, Asia, the Middle East as well as South America.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
23 minutes ago
- Scottish Sun
NHS first in the world to roll out ‘trogan horse' cancer treatment that ‘drastically slows disease'
A "TROJAN HORSE" therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a world first. It can stop the blood cancer myeloma from progressing for nearly three times longer than current therapies. 2 Paul Silvester having his treatment at Royal Hallamshire Hospital in Sheffield. Credit: PA The treatment, known as belantamab mafodotin or Blenrep, is an advanced form of chemotherapy. It delivers a powerful dose of cancer-killing medication directly into cancer cells, while limiting damage to healthy cells, reducing the risk of harsh side effects. Around 1,500 people a year with multiple myeloma, a rare, incurable cancer of the bone marrow, are expected to benefit from the treatment. Paul Silvester, 60, from Sheffield, is one of the first patients to receive the new drug through an early access programme. Diagnosed with myeloma in July 2023, Paul was initially given a different treatment, but when it failed to stop his cancer from progressing, doctors turned to belantamab mafodotin. 'I feel like this treatment has brought the party balloons back in the house,' he said. 'It has been amazing - within the first two or three weeks, after the first dose, I was in remission. "It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. "I've been feeling well and I'm still quite active - that's what's important in terms of your quality of life. "One of my daughters is graduating from university in October and it's a goal for me to be there." British rock legend reveals he's fighting aggressive blood cancer and is undergoing treatment The therapy, developed by GlaxoSmithKline, is administered via infusion every three weeks alongside two other drugs: bortezomib and dexamethasone. Clinical trials showed it could delay the progression of myeloma for around three years, compared to just over a year for patients receiving commonly used drug daratumumab with the same combination. Following new guidance from NICE (the National Institute for Health and Care Excellence), the drug has now been approved for widespread NHS use in England. It's the first health system in the world to offer it routinely. Patients who have relapsed or not responded to earlier treatments will now be eligible for the therapy. The treatment has been nicknamed a 'Trojan horse' because of how it works. 2 Much like the famous story from ancient Greek mythology where soldiers hid inside a giant wooden horse to secretly enter the city of Troy, this drug hides a toxic payload inside an antibody that tricks cancer cells into letting it in. Once inside, it releases a powerful, cell-killing molecule that destroys the cancer from within, while sparing surrounding healthy cells. 'New hope' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at NICE, added: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. "This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer." Myeloma UK, a charity supporting those with blood cancer, has also welcomed the news. Shelagh McKinlay, its director of research and advocacy, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth added: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. "By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country."
The Sun
27 minutes ago
- The Sun
NHS first in the world to roll out ‘trogan horse' cancer treatment that ‘drastically slows disease'
A "TROJAN HORSE" therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a world first. It can stop the blood cancer myeloma from progressing for nearly three times longer than current therapies. 2 The treatment, known as belantamab mafodotin or Blenrep, is an advanced form of chemotherapy. It delivers a powerful dose of cancer-killing medication directly into cancer cells, while limiting damage to healthy cells, reducing the risk of harsh side effects. Around 1,500 people a year with multiple myeloma, a rare, incurable cancer of the bone marrow, are expected to benefit from the treatment. Paul Silvester, 60, from Sheffield, is one of the first patients to receive the new drug through an early access programme. Diagnosed with myeloma in July 2023, Paul was initially given a different treatment, but when it failed to stop his cancer from progressing, doctors turned to belantamab mafodotin. 'I feel like this treatment has brought the party balloons back in the house,' he said. 'It has been amazing - within the first two or three weeks, after the first dose, I was in remission. "It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. "I've been feeling well and I'm still quite active - that's what's important in terms of your quality of life. "One of my daughters is graduating from university in October and it's a goal for me to be there." British rock legend reveals he's fighting aggressive blood cancer and is undergoing treatment The therapy, developed by GlaxoSmithKline, is administered via infusion every three weeks alongside two other drugs: bortezomib and dexamethasone. Clinical trials showed it could delay the progression of myeloma for around three years, compared to just over a year for patients receiving commonly used drug daratumumab with the same combination. Following new guidance from NICE (the National Institute for Health and Care Excellence), the drug has now been approved for widespread NHS use in England. It's the first health system in the world to offer it routinely. Patients who have relapsed or not responded to earlier treatments will now be eligible for the therapy. The treatment has been nicknamed a 'Trojan horse' because of how it works. 2 Much like the famous story from ancient Greek mythology where soldiers hid inside a giant wooden horse to secretly enter the city of Troy, this drug hides a toxic payload inside an antibody that tricks cancer cells into letting it in. Once inside, it releases a powerful, cell-killing molecule that destroys the cancer from within, while sparing surrounding healthy cells. 'New hope' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at NICE, added: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. "This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer." Myeloma UK, a charity supporting those with blood cancer, has also welcomed the news. Shelagh McKinlay, its director of research and advocacy, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth added: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. "By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country."
Rhyl Journal
34 minutes ago
- Rhyl Journal
‘Cover-ups' surrounding care of Nottingham attack killer, victim's mother claims
Valdo Calocane, who had been diagnosed with paranoid schizophrenia, killed three people – 19-year-old students Grace O'Malley-Kumar and Barnaby Webber and 65-year-old caretaker Ian Coates – and attempted to kill three more in Nottingham in June 2023. A February report into the care received by Calocane detailed how he was not forced to have long-lasting antipsychotic medication because he did not like needles, and how other patients at Nottinghamshire Healthcare NHS Foundation Trust also went on to commit 'extremely serious' acts of violence. Families of the victims met with Health Secretary Wes Streeting on Monday and said they told him they want the names of staff involved in treating Calocane to be made public. Speaking on ITV's Good Morning Britain on the second anniversary of the attack, Barnaby Webber's mother Emma Webber said of Calocane's care: 'We quite often say, imagine anything that could go wrong, did go wrong and Wes Streeting actually, to quote him, he said 'sunlight is the best disinfectant'. 'That's appropriate but, actually, I would say it's simpler than that. 'I think truth is and once you've got the truth, then you've got somewhere to begin, and we're still getting cover-ups, we're still getting mistruths and we're still getting those push-aside emails 'well, the trust will deal with that, or the inquiry will deal with that'. 'But, no, we're not going to stop. 'I don't know when they'll learn that we will not stop until we get those answers.' Ms Webber added that the families' calls for transparency were 'not a witch hunt'. She said: 'I'm sure it can come across that we as families are just so vociferous in finding answers and trying to deal with our grief and our anger and rage at what happened. 'But it's much deeper than that, and it's greater than that, because there are individuals out there that they're posing a risk themselves, but they're posing a risk to the public, and we're not on a witch hunt in what we're doing. 'We do have the statutory inquiry coming up but that shouldn't stop individuals who, just as basic as failing to do their jobs properly, from being held to account, and that's through the professional means. 'I cannot understand how the NHS have not been able to confirm that anyone has had any disciplinary action against them for what they did or didn't do during his care.' Grace O'Malley-Kumar's father, Dr Sanjoy Kumar, told the programme that the families do not have 'detailed answers' and called for 'full transparency' and 'true accountability'. He said: 'At this juncture, I think it's turned into a national representation case for us, because I think what we've realised is that every family that goes through a horrific tragedy like us, they're not given answers, and they're given a lot of kerfuffle about what happened when, that's all very interesting, the timelines are interesting, but what we want is true accountability. 'Because when we have accountability, we can then have change and positive change for the country, and we've not had that, and that's been really, really frustrating.' Calocane was sentenced to an indefinite hospital order in January 2024 after admitting manslaughter by diminished responsibility and attempted murder. He was admitted to hospital and sectioned under the Mental Health Act four times between 2020 and 2022 because of his violent behaviour and refusal to take his medication, before NHS services lost track of him and discharged him in the months before the attacks. Three reports, including one by the Care Quality Commission (CQC), described failings in his care but none included practitioners' names, Dr Kumar said after meeting Mr Streeting. On Friday, the families of the victims will hold a memorial walk through Nottingham to remember their loved ones two years after their deaths. They will meet at St Paul's Church in Lenton Road at 11.30am before walking to the two locations of the attacks. During the interview with Good Morning Britain, Ms Webber said she had a 'visceral reaction' to returning to the city, adding that 'feels almost like it was yesterday' that the attack happened. She added that the group wanted to 'walk in peace and love', and that anyone who wanted to join was 'very welcome'. In a statement, Ifti Majid, chief executive of Nottinghamshire Healthcare NHS Foundation Trust, said: 'We are committed to giving our fullest co-operation and support to the Nottingham Inquiry which has already begun to request documentary evidence from ourselves and other organisations in relation to the devastating events of June 2023. 'It would be inappropriate to comment further at this stage.' The Department of Health and Social Care has been contacted for comment.
